MSA Japanese Newsletter: Advancing the Next Generation of Genetic Medicines Through Precision RNA Delivery

Nava Therapeutics CEO Federico Mingozzi, Ph.D., discusses the advances in ionizable lipid chemistry fueling investment in in vivo CAR-T, how the company’s proprietary lipid nanoparticle (LNP) platform delivers RNA therapies to tissues beyond the liver, and Nava’s evolution from a delivery platform into a company advancing its own pipeline of in vivo CAR-T cell and RNA therapies for autoimmune diseases and other therapeutic areas. The post MSA Japanese Newsletter: Advancing the Next Generation of Genetic Medicines Through Precision RNA Delivery appeared first on NavaTx .